Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

To evaluate the antigenic relationship between bat mumps virus (BMV) and the JL5 vaccine strain of mumps virus (MuVJL5), we rescued a chimeric virus bearing the F and HN glycoproteins of BMV in the background of a recombinant JL5 genome (rMuVJL5). Cross-reactivity and cross-neutralization between this chimeric recombinant MuV bearing the F and HN glycoproteins of BMV (rMuVJL5-F/HNBMV) virus and rMuVJL5 were demonstrated using hyperimmune mouse serum samples and a curated panel of human serum. All mouse and human serum samples that were able to neutralize rMuVJL5 infection had cross-neutralizing activity against rMuVJL5-F/HNBMV. Our data suggest that persons who have neutralizing antibodies against MuV might be protected from infection by BMV.

Original publication

DOI

10.1093/infdis/jiw534

Type

Journal article

Journal

J Infect Dis

Publication Date

15/01/2017

Volume

215

Pages

209 - 213

Keywords

cross-reactive antibodies, mumps virus, neutralizing antibodies, viral envelope proteins, zoonoses, Adolescent, Adult, Animals, Antibodies, Neutralizing, Antibodies, Viral, Chiroptera, Cross Reactions, Female, Humans, Mice, Inbred BALB C, Middle Aged, Mumps virus, Young Adult